Literature DB >> 20817228

Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery.

G Ferrandina1, P A Margariti, D Smaniotto, M Petrillo, M G Salerno, A Fagotti, G Macchia, A G Morganti, N Cellini, G Scambia.   

Abstract

OBJECTIVE: Preoperative chemoradiation (CT/RT) has been shown to achieve encouraging results in terms of clinical outcome in locally advanced cervical cancer (LACC). The study aims at analyzing the long-term results of this multimodal approach in a single institution series of 184 cases.
METHODS: Patients underwent whole pelvic irradiation combined with cisplatin and 5-fluorouracil. After evaluation of clinical response, patients were triaged to surgery. Surgical morbidity was classified according to Chassagne grading system. Univariate and multivariate analyses were used to assess the prognostic and predictive role of clinicopathological parameters.
RESULTS: Clinical response was observed in 96.1% of cases. A total of 174 cases were submitted to radical surgery: 124 patients (71.3%) showed complete/microscopic pathological response. In multivariate analysis, clinical response, stage of disease, and histotype predicted response to CT/RT. With a median follow-up of 58 months, recurrence and death of disease were observed in 42 and 40 patients, respectively. The 5-year DFS was 75.5%, while the 5-year OS was 77.4%. Patients with no residual disease showed a significant longer DFS than patients with microscopic (p value = 0.0128), and macroscopic (p value = 0.0001) residual tumor after treatment. In multivariate analysis, residual tumor and stage of disease were the two most relevant prognostic factors for DFS and OS. As far as long-term toxicity is concerned, 8 out of 22 complications were grade 3/4.
CONCLUSION: Preoperative CT/RT is worth further investigation in LACC patients, providing encouraging survival outcomes and a favourable long-term toxicity profile.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20817228     DOI: 10.1016/j.ygyno.2010.08.004

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

1.  The PRICE study: The role of conventional and diffusion-weighted magnetic resonance imaging in assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery.

Authors:  A L Valentini; M Miccò; B Gui; M Giuliani; E Rodolfino; A M Telesca; T Pasciuto; A Testa; M A Gambacorta; G Zannoni; V Rufini; A Giordano; V Valentini; G Scambia; R Manfredi
Journal:  Eur Radiol       Date:  2018-01-09       Impact factor: 5.315

2.  Treatment of cervical cancer: the importance of a multidisciplinary team approach.

Authors:  J Alejandro Pérez Fidalgo; Ana Hernández Machancoses; Víctor Martín González; Andrés Cervantes
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

3.  MRI anatomy of parametrial extension to better identify local pathways of disease spread in cervical cancer.

Authors:  Anna Lia Valentini; Benedetta Gui; Maura Miccò; Michela Giuliani; Elena Rodolfino; Valeria Ninivaggi; Marta Iacobucci; Marzia Marino; Maria Antonietta Gambacorta; Antonia Carla Testa; Gian Franco Zannoni; Lorenzo Bonomo
Journal:  Diagn Interv Radiol       Date:  2016 Jul-Aug       Impact factor: 2.630

4.  The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study.

Authors:  Vittoria Rufini; Angela Collarino; Maria Lucia Calcagni; Guido Maria Meduri; Valentina Fuoco; Tina Pasciuto; Antonia Carla Testa; Gabriella Ferrandina; Maria Antonietta Gambacorta; Maura Campitelli; Benedetta Gui; Gianfranco Zannoni; Riccardo Manfredi; Giovanni Scambia; Alessandro Giordano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236

5.  Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.

Authors:  Maki Tanioka; Satoshi Yamaguchi; Muneaki Shimada; Shoji Nagao; Kazuhiro Takehara; Masato Nishimura; Satoshi Morita; Shunichi Negoro; Kiyoshi Fujiwara; Junzo Kigawa
Journal:  Med Oncol       Date:  2017-07-05       Impact factor: 3.064

6.  Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome.

Authors:  K Vandecasteele; A Makar; R Van den Broecke; L Delrue; H Denys; K Lambein; B Lambert; M van Eijkeren; P Tummers; G De Meerleer
Journal:  Strahlenther Onkol       Date:  2012-04-19       Impact factor: 3.621

7.  Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical cancer: a dose-escalation study.

Authors:  Gabriella Macchia; Savino Cilla; Francesco Deodato; Francesco Legge; Aida Di Stefano; Vito Chiantera; Giovanni Scambia; Vincenzo Valentini; Alessio G Morganti; Gabriella Ferrandina
Journal:  Br J Radiol       Date:  2015-09-21       Impact factor: 3.039

8.  Local Radiotherapy or Chemotherapy for Oligo-recurrent Cervical Cancer in Patients With Prior Pelvic Irradiation.

Authors:  Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Ryuji Hamamoto; Jun Itami
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

Review 9.  Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB.

Authors:  Lucas Minig; María Guadalupe Patrono; Nuria Romero; Juan Francisco Rodríguez Moreno; Jesús Garcia-Donas
Journal:  World J Clin Oncol       Date:  2014-05-10

10.  Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis.

Authors:  Giovanna Mantegna; Marco Petrillo; Gilda Fuoco; Laura Venditti; Serena Terzano; Luigi Pedone Anchora; Giovanni Scambia; Gabriella Ferrandina
Journal:  BMC Cancer       Date:  2013-03-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.